Endpoint
Hospital length of stay
CAT:outcome/hospital-length-of-stayreported in days14 findings from 8 compounds
What moved it
How to read these marks14 findings · 8 compounds · 7 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| methylene blue | down | 2 | Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. |
| L-glutamine | down 4 · no effect 2 | 6 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| fluconazole | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| magnesium(2+) | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| meloxicam | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| N-acetyl-L-cysteine | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| calciol | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
| L-arginine | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
7 findings
methylene blue — decreases
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.Findingreplicated ×1“The results showed that MB reduced the hospital LOS in patients with distributive shock (MD: −1.97; 95% CI −3.82 to −0.11; p=0.04; table 2).”
Quoted verbatim from Effect of methylene blue on outcomes in patients with distributive shock: a meta-analysis of randomised controlled trials.. - Study
- meta-analysis
- Participants
- 111
- Population
- adults with distributive shock (septic shock, vasoplegic syndrome, ischaemia-reperfusion injury); secondary endpoint; 2 trials, n = 111
Effect -1.97 mean difference, 95% CI -3.82 to -0.11
Effect of methylene blue on outcomes in patients with distributive shock: a meta-analysis of randomised controlled trials.2024PMID:38216185Permalink
methylene blue — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Consequently, the mean length of hospital stay was significantly shorter for patients receiving MBI (3.80 ± 0.85 days) than for controls (5.43 ± 1.01 days; P <.001).”
Quoted verbatim from The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study.. - Study
- RCT
- Participants
- 60
- Dose
- single intraoperative subcutaneous infiltration of 0.5-1 mL of 0.1% methylene blue per incision site, total not exceeding 5 mL
- Population
- adults with mixed haemorrhoids after Milligan-Morgan haemorrhoidectomy; secondary endpoint; reported in days; both arms received the same on-demand intravenous lornoxicam protocol
The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study.2026PMID:41686620Permalink
L-glutamine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×3“The pooled results showed that Gln supplementation significantly reduced the total length of hospital stay (MD = −3.41, 95% CI: −4.93 to −1.88, P < 0.0001; Figure 7).”
Quoted verbatim from Efficacy of Glutamine in Treating Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Severe acute pancreatitis patients, pooled across parenteral and enteral glutamine-supplemented nutrition trials
Effect -3.41 mean difference, 95% CI -4.93 to -1.88
Efficacy of Glutamine in Treating Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis.2022PMID:35774540Permalink
N-acetyl-L-cysteine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“However, pooled data from 2 studies assessing hospital LOS indicated a significantly shorter LOS in the NAC group than in the control group (MD = −3.84 days; 95% CI: −7.44 to −0.24; Table 3).”
Quoted verbatim from Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Critically ill ICU patients with underlying respiratory disease; pooled across 2 randomized trials, NAC in addition to standard care versus placebo or regimens without NAC; reported in days
Effect -3.84 mean difference, 95% CI -7.44 to -0.24
Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.2026PMID:42780769Permalink
L-glutamine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“However, enteral GLN therapy was related to a reduction of hospital LOS (MD, -2.85; 95% CI, -5.27 to -0.43; p = 0.02).”
Quoted verbatim from Glutamine enteral therapy for critically ill adult patients: An updated meta-analysis of randomized controlled trials and trial sequential analysis.. - Study
- meta-analysis
- Population
- Adult critically ill patients receiving enteral glutamine supplementation (meta-analysis of 18 RCTs).
Glutamine enteral therapy for critically ill adult patients: An updated meta-analysis of randomized controlled trials and trial sequential analysis.2024PMID:38041938Permalink
L-glutamine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Glutamine supplementation was also associated with a lower rate of infectious complications (RR, 0.81; 95% CI, 0.64-1.00) and a shorter hospital stay (-2.6 days; 95% CI, -4.5 to -0.7).”
Quoted verbatim from Glutamine supplementation in serious illness: a systematic review of the evidence.. - Study
- meta-analysis
- Population
- surgical and critically ill adult patients (pooled meta-analysis of 14 randomised trials, various glutamine doses and routes)
Effect -2.6 mean difference, 95% CI -4.5 to -0.7
Glutamine supplementation in serious illness: a systematic review of the evidence.2002PMID:12352035Permalink
Show the remaining 1
L-glutamine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“Use of glutamine compared with an isonitrogenous control led to a reduction in length of hospital stay (mean stay -5.65 days, 95% confidence interval (CI) -8.09 to -3.22) and reduced mortality (pooled risk ratio (RR) 0.25, 95% CI 0.08 to 0.78).”
Quoted verbatim from Immunonutrition as an adjuvant therapy for burns.. - Study
- meta-analysis
- Population
- patients with severe burn injury; glutamine (7 of 16 included RCTs) versus isonitrogenous control diet
Effect -5.65 mean difference, 95% CI -8.09 to -3.22
Immunonutrition as an adjuvant therapy for burns.2014PMID:25536183Permalink
Measured, no effect detected
7 findings
magnesium(2+) — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The average duration of hospital stay did not show any significant difference between the magnesium group and control group (7.32 ± 5.37 days vs. 7.28 ± 4.65 days; P = 0.84).”
Quoted verbatim from A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients.. - Study
- RCT
- Participants
- 60
- Dose
- 300 mg daily as magnesium citrate capsules, from admission to discharge
- Population
- Hospitalised adults aged 18-70 with moderate COVID-19 (60 analysed, 30 per arm)
A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients.2024PMID:38654355Permalink
meloxicam — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The duration of hospital stay was numerically shorter for subjects who received meloxicam IV versus placebo, but the difference was not statistically significant (P =.4935) (Supplemental Digital Content 3, Table S2).”
Quoted verbatim from Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.. - Study
- RCT
- Dose
- 30 mg IV bolus before incision, then every 24 hours
- Population
- Adults undergoing elective primary total knee arthroplasty; hospital stay after surgery
Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.2021PMID:33502533Industry fundedPermalink
fluconazole — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The total length of hospital stay was no different between the fluconazole group and the placebo group (weight mean difference = -0.4 days, 95% CI = -10.35 to 9.54, P = 0.94; I2 = 52.4%).”
Quoted verbatim from The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.. - Study
- meta-analysis
- Dose
- 100 to 800 mg/day
- Population
- Immunocompetent high-risk surgical adult patients in randomised trials of prophylactic fluconazole versus placebo; pooled routes (five intravenous, one enteral, one either)
Effect -0.4 mean difference, 95% CI -10.35 to 9.54
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.2005PMID:16280069Industry fundedPermalink
L-glutamine — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1“The length of hospital stay was reported in 14 trials, in which a total of 2,777 patients were enrolled; however, the patient length of stay was not affected by glutamine supplementation.”
Quoted verbatim from The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Participants
- 2,777
- Population
- critically ill patients
The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials.2014PMID:24401636Permalink
calciol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Median (interquartile range) length of stay was not significantly different between the vitamin D3 (7.0 [4.0-10.0] days) and placebo groups (7.0 [5.0-13.0] days) (log-rank P = .59; unadjusted hazard ratio for hospital discharge, 1.07 [95% CI, 0.82-1.39]; P = .62).”
Quoted verbatim from Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.. - Study
- RCT
- Dose
- single oral dose of 200,000 IU vitamin D3 versus placebo
- Population
- Hospitalised adults with moderate to severe COVID-19 at two sites in Sao Paulo, Brazil
Effect 1.07 hazard ratio, 95% CI 0.82 to 1.39
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.2021PMID:33595634Permalink
L-glutamine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1“We found that glutamine supplementation does not have a statistically significant effect on the incidence of systemic infection (typical relative risk 1.02 (95% confidence interval 0.92 to 1.13); typical risk difference 0.01 (95% confidence interval -0.03 to 0.05)), necrotising enterocolitis (typical relative risk 1.02 (95% confidence interval 0.79 to 1.33); typical risk difference 0.00 (95% confidence interval -0.02 to 0.03)), days to full enteral nutrition (weighted mean difference -1.1 days (95% confidence interval -3.4 to 1.2)), or duration of hospital stay (weighted mean difference 0.65 days (95% confidence interval -2.9 to 4.2)).”
Quoted verbatim from Glutamine supplementation to prevent morbidity and mortality in preterm infants.. - Study
- meta-analysis
- Population
- very low birth weight preterm infants (pooled meta-analysis of six randomised trials, enteral and parenteral)
Effect 0.65 mean difference, 95% CI -2.9 to 4.2
Glutamine supplementation to prevent morbidity and mortality in preterm infants.2005PMID:15674878Permalink
Show the remaining 1
L-arginine — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no significant difference in hospital length of stay (4.1 ± 01.8 versus 4.8 ± 2.5 days, P=0.34), although a trend favored the arginine arm, and total opioid use was strongly correlated with the duration of the admission (r=0.86, P<0.0001).”
Quoted verbatim from A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.. - Study
- RCT
- Dose
- L-arginine 100 mg/kg three times daily for 5 days or until discharge, versus placebo
- Population
- Children with sickle cell disease hospitalised with vaso-occlusive pain episodes (38 children, 56 episodes)
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.2013PMID:23645695Permalink
How it is measured
Elapsed time from hospital admission to hospital discharge, taken from the medical record. The reporting unit is recorded with each finding, because sources differ, and so is the clinical setting, because admissions for different reasons have incomparable baselines.
Measured, not recorded
- Subject
- hospital length of stay
- Measurements
- 35 measurements
- Recorded as a finding
- No
Show what was measured
hospital length of stay
no effect
There were no significant differences in time to extubation and hospital length of stay.
PMID:38722114 · both readings recorded this
hospital length of stay
no effect
Not recorded as a finding: Only sentence is agentless and does not name quercetin, and groups several endpoints together.
However, total morphine consumption, functional activity, incidence of nausea and vomiting, and hospital length of stay were comparable between groups, with no significant differences in adverse effects.
PMID:40687903 · both readings recorded this
Hospital length of stay
unclear, MD 37.80 d less; 95% CI 143.03 d fewer to 67.43 d more, n = 10
One RCT (n = 10 participants) examined hospital LOS, demonstrating an uncertain effect with ketamine (MD, 37.80 d less; 95% CI, 143.03 d fewer to 67.43 d more; very low certainty; Table 2; Appendix 4, https://links.lww.com/CCX/B624).
PMID:42042859 · both readings recorded this
hospital length of stay
no effect, MD -0.07 days (95% CI -0.66 to 0.53), n = 1227
Magnesium did not significantly affect LOS (weighted mean difference -0.07 days of stay, 95% CI -0.66 to 0.53).
PMID:15831645 · one of two readings recorded this
Hospital length of stay
no effect, p = 0.34, n = 38
hospital length of stay (4.1 ± 01.8 versus 4.8 ± 2.5 days, P=0.34)
PMID:23645695 · one of two readings recorded this
hospital length of stay
no effect, WMD -1.48 days (95% CI -3.93 to 0.98), p = 0.24, n = 2777
Not recorded as a finding: two-sided null stated ('No difference was found between the groups') but the sentence refers to 'the groups' rather than naming glutamine directly
No difference was found between the groups with respect to the length of hospital stay (WMD, -1.48 days; 95% CI, -3.93 to 0.98; P = 0.24).
PMID:24401636 · one of two readings recorded this
hospital length of stay
decreases, p = 0.02
significant reduction in hospital LOS (WMD -2.56, 95% CI -4.71, -0.42, P = 0.02)
PMID:24745648 · one of two readings recorded this
hospital length of stay
decreases, p = 0.023
LoS [MD = -6.8 (95% CI -12.6 to -0.9) days, p = 0.023
PMID:24844870 · one of two readings recorded this
hospital length of stay
decreases, MD -3.46 days (95% CI -4.61 to -2.32)
Not recorded as a finding: sentence names 'the intervention group' vs 'the control group' rather than glutamine directly; abstract-only source
We found that the length of hospital stay was shorter in the intervention group than in the control group (MD -3.46 days, 95% CI -4.61 to -2.32, P < 0.0001, I² = 63%, low quality evidence).
PMID:25199493 · one of two readings recorded this
hospital length of stay
no effect, p = 0.688
HLOS (WMD = 0.23 days; 95% CI = −0.88 to 1.33 days; P = 0.688; Figure 4)
PMID:25212718 · one of two readings recorded this
hospital length of stay
increases, PAI mean 2.2 days (range 2-5) vs PEI mean 1.7 days (range 2-3)
Data on the duration of hospital stay were available from one trial for the comparison PEI versus PAI showing a significantly shorter hospital stay for the participants treated with PEI versus PAI.
PMID:25620061 · one of two readings recorded this
hospital length of stay
no effect, p = 0.45
higher-quality trials showed a significant reduction (WMD = −7.42; 95% CI, −11.89 to −2.94; P = 0.001), although low-quality trials had no effect (P = 0.45)
PMID:25879776 · one of two readings recorded this
hospital length of stay
decreases, p = 0.001
higher-quality trials showed a significant reduction (WMD = −7.42; 95% CI, −11.89 to −2.94; P = 0.001), although low-quality trials had no effect (P = 0.45)
PMID:25879776 · one of two readings recorded this
hospital length of stay
no effect, p = 0.19
showed a trend toward reduction in hospital LOS, without reaching statistical significance (WMD = −3.71; 95% CI, −9.31 to 1.88; P = 0.19)
PMID:25879776 · one of two readings recorded this
hospital length of stay
decreases, p = 0.01
hospital LOS (MD -2.30 days, 95% CI -4.14, -0.45, p = 0.01)
PMID:28361751 · one of two readings recorded this
hospital length of stay
no effect, p = 0.35, n = 1650
1,650 patients for hospital length of stay (HLoS) (MD -0.21 days, 95% CI -0.64 to 0.23; I2 = 89%; p = 0.35)
PMID:31071081 · one of two readings recorded this
Hospital length of stay
no effect, p = 0.92
Hospital LOS (day) | 14 (11–21) | 13.5 (9–26) | 0.5 (− 4 to 4) | 0.92
PMID:32780166 · one of two readings recorded this
hospital length of stay
no effect, MD -0.75 days, 95% CI -2.27 to 0.77, n = 2238
Regarding hospital LOS, no significant difference was found between the groups (MD, −0.75; 95% CI: −2.27 to 0.77; I2 = 85%).
PMID:36316858 · one of two readings recorded this
Hospital length of stay
no effect, p = 0.06
Hospital LOS(d), mean ± SD | 31.1 ± 36.7 | 37.0 ± 44.4 | 25.7 ± 27.1 | 0.060
PMID:36440551 · one of two readings recorded this
hospital length of stay
no effect, median 6 days (l-Arg) vs 7 days (placebo) to discharge from enrollment, p = 0.42
Not recorded as a finding: measured from study enrollment rather than hospital admission, which the outcome definition requires; patients were already hospitalized before enrollment (up to 15 days after symptom onset)
The median time to discharge from enrollment to the study was 6 days in the l-Arg group (95% CI: 4.4, 7.6) and 7 days in the placebo group (95% CI: 4.4, 9.6); P = 0.42.
PMID:36513483 · one of two readings recorded this
Hospital length of stay
no effect, p = 0.88, n = 106
Hospital LOS, median (IQR)† | 22 (9–48) | 18.5 (12–36) | 0.88
PMID:36870070 · one of two readings recorded this
hospital length of stay
no effect
Mortality, number of operations, stroke, and hospital length of stay were similar between cohorts
PMID:37875155 · one of two readings recorded this
Hospital length of stay
decreases, MD -2.85 (95% CI -5.27 to -0.43), p = 0.02
However, enteral GLN therapy was related to a reduction of hospital LOS (MD, -2.85; 95% CI, -5.27 to -0.43; p = 0.02).
PMID:38041938 · one of two readings recorded this
hospital length of stay
decreases, MD -1.97 (95% CI -3.82 to -0.11), p = 0.04
The results showed that MB reduced the hospital LOS in patients with distributive shock (MD: −1.97; 95% CI −3.82 to −0.11; p=0.04; table 2).
PMID:38216185 · one of two readings recorded this
hospital length of stay
increases, MD 2.05 days, 95% CI 0.15-3.95, n = 565
The use of HAT regimen was associated with increased hospital LOS by 2 days compared to standard sepsis care and/or placebo (mean difference [MD] 2.05 days, 95% CI: 0.15-3.95; see Fig. 4a) based on 4 RCTs (N = 565).
PMID:38870923 · one of two readings recorded this
Hospital length of stay
no effect
However, total morphine consumption, functional activity, incidence of nausea and vomiting, and hospital length of stay were comparable between groups
PMID:40687903 · one of two readings recorded this
hospital length of stay
no effect, 6.0 days both groups, p = 0.645, n = 217
There was also no statistically significant difference in the length of hospital stay (6.0 [IQR, 5.0, 6.0] days vs. 6.0 [IQR, 5.0, 6.0] days; P = 0.645) between the two groups.
PMID:40696945 · one of two readings recorded this
hospital length of stay
no effect, p = 0.6, n = 38
Hospital length of stay, median (IQR), days | 19 (13–27) | 19 (13–23) | 18 (13–31) | 0.6
PMID:40974583 · one of two readings recorded this
hospital length of stay
decreases, p = 0.005, n = 24
The controls were hospitalized for a more extended time compared to the EPA-rich fish oil (p = 0.005).
PMID:41254027 · one of two readings recorded this
Hospital length of stay
no effect, median 5 days both groups, p = 0.623, n = 109
Median LOS was 5 days (IQR: 3–7), with no group difference (p=0.623).
PMID:41592826 · one of two readings recorded this
Hospital length of stay
no effect, p = 0.13, n = 17
Hospital LOS, days | 33 [31–51] | 24 [18–38] | 0.13
PMID:41790037 · one of two readings recorded this
Hospital length of stay
no effect, p = 0.68, n = 2721
Hospital LOS (days) | 10 | 2721 | -0.33 [-1.91, 1.25] | 0.68 | 45% | 0.06
PMID:42310686 · one of two readings recorded this
hospital length of stay
decreases, p = 0.04
estimated difference −1.68 days, 95% CI −3.28 to −0.08, p = 0.040
PMID:42356168 · one of two readings recorded this
hospital length of stay
no effect
Sun et al. (2023) found no significant difference between groups (median 8 days [IQR 8–10] vs. 8 days [IQR 7–10])
PMID:42356168 · one of two readings recorded this
hospital length of stay
decreases
pooled data from 2 studies assessing hospital LOS indicated a significantly shorter LOS in the NAC group than in the control group (MD = −3.84 days; 95% CI: −7.44 to −0.24; Table 3)
PMID:42780769 · one of two readings recorded this
Sources cited
14 papers
- Subject
- hospital length of stay
- Findings
- 14
- Papers
- 14
Clinical effects of N-acetylcysteine in ICU patients with respiratory disease: a systematic review and meta-analysis.record2026PMID:427807691 finding
The effect of methylene blue infiltrating injection on anal pain after Milligan-Morgan surgery: A randomized controlled clinical study.record2026PMID:416866201 finding
A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients.record2024PMID:386543551 finding
Effect of methylene blue on outcomes in patients with distributive shock: a meta-analysis of randomised controlled trials.record2024PMID:382161851 finding
Glutamine enteral therapy for critically ill adult patients: An updated meta-analysis of randomized controlled trials and trial sequential analysis.record2024PMID:380419381 finding
Efficacy of Glutamine in Treating Severe Acute Pancreatitis: A Systematic Review and Meta-Analysis.record2022PMID:357745401 finding
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.record2021PMID:335956341 finding
Safety and Efficacy of Perioperative Intravenous Meloxicam for Moderate-to-Severe Pain Management in Total Knee Arthroplasty: A Randomized Clinical Trial.record2021PMID:335025331 finding
Immunonutrition as an adjuvant therapy for burns.record2014PMID:255361831 finding
The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials.record2014PMID:244016361 finding
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.record2013PMID:236456951 finding
Glutamine supplementation to prevent morbidity and mortality in preterm infants.record2005PMID:156748781 finding
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis.record2005PMID:162800691 finding
Glutamine supplementation in serious illness: a systematic review of the evidence.record2002PMID:123520351 finding